Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MCC-based 13% drug loaded tablets
MCC-based 13% drug loaded · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | 100mg MCC-based 13% drug-loaded tablets |
| Treatment B | EXPERIMENTAL | 100mg mannitol-based 38% drug-loaded tablets |
| Treatment C | EXPERIMENTAL | 150mg MCC-based 13% drug-loaded tablets |
| Treatment D | EXPERIMENTAL | 150mg mannitol-based 38% drug-loaded tablets |
| Name | Type | Description |
|---|---|---|
| MCC-based 13% drug loaded tablets | DRUG | 50mg tablets, dosed as 2 tablets (100mg total) |
| Mannitol-based 38% drug-loaded tablet | DRUG | One 100mg tablet |
Inclusion Criteria: * Males and nonlactating, non childbearing potential females from 18 to 55 years, inclusive and with a weight of at least 50 kg and BMI between 18 and 30 kg/m2, inclusive * Females must have a negative pregnancy test at screening and on admission to the study center of each peri...
MCC-based 13% drug loaded is an investigational small molecule formulation developed by AstraZeneca PLC. It is described as MCC-based 13% drug loaded tablets. The formulation has been studied in a Phase 1 clinical trial in healthy volunteers, and its specific therapeutic indication has not been disclosed.
MCC-based 13% drug loaded is being developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the clinical program for this formulation.
MCC-based 13% drug loaded is in Phase 1 clinical development. It is an investigational formulation and has not been approved by the FDA. The Phase 1 program includes one completed trial with 88 participants.
MCC-based 13% drug loaded has been evaluated in one clinical trial, NCT01645085, titled "A Study to Assess the Bioequivalence of R406 in Healthy Volunteers When Given 100mg and 150 mg of Fostamatinib." This Phase 1 trial was completed, enrolled 88 healthy volunteers, and was conducted in the United States.
Yes, MCC-based 13% drug loaded tablets is another name for MCC-based 13% drug loaded. Both terms refer to the same investigational formulation developed by AstraZeneca PLC.